Resistance of estrogen receptor positive (ER␣ϩ) breast cancers to antiestrogens is a major factor in the mortality of this disease. Although activation of ER␣ in the absence of ligand is hypothesized to contribute to this resistance, the potency of this mechanism in vivo is not clear. Epidemiologic studies have strongly linked prolactin (PRL) to both development of ER␣ϩ breast cancer and resistance to endocrine therapies. Here we employed genetically modified mouse models to examine the ability of PRL and cross talk with TGF␣ to activate ER␣, using a mutated ER␣, ER␣(G525L), which is refractory to endogenous estrogens. We demonstrate that PRL promotes pubertal ER␣-dependent mammary ductal elongation and gene expression in the absence of estrogen, which are abrogated by the antiestrogen, ICI 182,780 (ICI). PRL and TGF␣ together reduce sensitivity to estrogen, and 30% of their combined stimulation of ductal proliferation is inhibited by ICI, implicating ligand-independent activation of ER␣ as a component of their interaction. However, PRL/TGF␣-induced heterogeneous ER␣ϩ tumors developed more rapidly in the presence of ICI and contained altered transcripts for surface markers associated with epithelial subpopulations and increased signal transducer and activator of transcription 5b expression. Together, these data support strong interactions between PRL and estrogen on multiple levels. Ligand-independent activation of ER␣ suggests that PRL may contribute to resistance to antiestrogen therapies. However, these studies also underscore ER␣-mediated moderation of tumor phenotype. In light of the high expression of PRL receptors in ER␣ϩ cancers, understanding the actions of PRL and cross talk with other oncogenic factors and ER␣ itself has important implications for therapeutic strategies. (Endocrinology 154: 4483-4492, 2013) 
M
ost breast cancers express estrogen receptor ␣ (ER␣ϩ). Fortunately, most of these cancers are sensitive to antiestrogen treatments, such as selective ER modulators or aromatase inhibitors. However, a substantial minority (25%-50%) are either resistant at the time of diagnosis or acquire resistance to these therapies (1) (2) (3) (4) . Because of the prevalence of ER␣ϩ breast cancer, antiestrogen-resistant tumors account for most breast cancer deaths. Understanding the mechanisms that lead to resistance is essential for identifying targets for effective treatment strategies. Epidemiologic studies have linked prolactin (PRL) to the development and therapeutic sensitivity of luminal breast cancer. Elevated PRL exposure increases the risk of developing ER␣ϩ tumors (5) . Many ER␣ϩ breast cancers also express PRL receptor (PRLR), and evidence for PRL action (circulating PRL, tumor PRLR expression) has been linked to resistance to antiestrogen therapies (6 -9) , metastatic disease, or other poor outcomes (10 -14) . Defining the mechanisms of cross talk between ER␣, estrogen, PRL, and growth factors has important implications for both understanding PRL actions and identifying therapeutic targets in breast cancer.
We have developed the neu-related-lipocalin (NRL)-PRL transgenic mouse as a preclinical model to examine the actions of PRL in this disease (15, 16) . The mammary epithelia of these mice express PRL, elevating local exposure similar to that observed in women (17, 18) . Consistent with the epidemiologic studies, nulliparous NRL-PRL females develop diverse aggressive carcinomas that resemble the luminal subtype of clinical breast cancer (19) . Despite ER␣ expression, advanced tumors do not respond to ovariectomy or supplemental 17␤-estradiol (19) . Transgenic PRL elevates mammary pErk1/2 and pAkt (20) , signaling cascades that are associated with phosphorylation of the N-terminal activation function 1 (AF-1) domain of ER␣ and subsequent activation even in the absence of estrogenic ligands (21) (22) (23) (24) . PRL also can induce phosphorylation of ER␣ in human breast cancer cell lines in vitro (25, 26) and induces recruitment of ER␣ to target genes (27) . These observations of PRL actions resemble those reported for growth factors that are also linked to resistance to estrogen-directed therapies for breast cancer (2, 3) . However, whether this mechanism plays a role in PRL action in the dynamic in vivo environment is unclear.
PRL also strongly potentiates growth factor signals in vitro and in vivo. In breast cancer cell lines, PRL cooperates with IGF-1 and epidermal growth factor (EGF) receptor ligands to prolong signaling through the ERK1/2 and AKT pathways, by modulation of the trafficking of the respective growth factor receptors (26, 28 -31) . PRL can also initiate phosphorylation of human epidermal growth factor receptor 2 (32) . Many of the carcinomas that develop in NRL-PRL females in vivo express high levels of erbB family receptors (33) . ErbB signals play important roles in normal mammary development as well as breast cancer (34, 35) . Transgenic mammary expression of the EGF receptor (EGFR) ligand, TGF␣, in combination with PRL, dramatically reduces tumor latency (28) . Strikingly, the combination of these 2 transgenes also abrogates the proliferative response of morphologically normal ducts to estrogen, as well as the interaction of estrogen and TGF␣ in tumorigenesis (26) . Although these observations indicate that the interaction of PRL and TGF␣ confers independence from estrogenic ligands for proliferation, they do not address a role for ER␣ itself.
In order to address the role of ligand-independent activation of ER␣, we have taken advantage of the genetically modified mouse expressing ER␣(G525L) (36) . This mutated ER␣ is refractory to 17␤-estradiol but retains responsiveness to the synthetic ER␣ agonist, propylpryrazoletriol (PPT) and responds to phosphorylation, permitting analysis of ligand-independent activation. Transgenic mammary PRL and TGF␣ expression, in conjunction with the antiestrogen ICI 182,780 (ICI), permit dissociation of these factors and estrogen, which is otherwise complicated by estrogenic regulation of the PRL and TGF␣ promoters (37, 38) . In combination, these mouse models enabled us to examine the ability of PRL to activate ER␣ in the absence of ligand and determine whether this leads to functionally important physiologic and pathologic consequences. Our findings demonstrate significant relevance of this mechanism in vivo and reveal the consequences of ER signals in PRL-TGF␣ cross talk in mammary tumorigenesis.
Materials and Methods

Reagents
The following antibodies were used for immunohistochemistry: Ki-67 (catalog no. 15580) from Abcam, ER␣ (sc-542), signal transducer and activator of transcription (Stat)5a (sc-1081), and Stat5b (sc-1656) from Santa Cruz Biotechnology, Inc. PPT was obtained from Orbiter Research, LCC. ICI (Fulvestrant) was obtained from AstraZeneca.
Mice
NRL-PRL [line 1647-13, TgN(Nrl-Prl)23EPS] and NRL-TGF␣ [line 1385-7, TgN(Nrl-tgfa)25EPS] mice, were generated in the FVB/N strain background as described elsewhere (15, 39) . The NRL promoter directs expression to mammary epithelial cells and is not affected by PRL or estrogen (15, 39) . Mice expressing a mutated ER␣ [ER␣(G525L)], which is not activated by 17␤-estradiol, were derived and maintained on a mixed background, as described elsewhere (36) . For experiments examining tumorigenesis, ER␣(G525L) mice were backcrossed 5 generations (N5) onto the FVB/N strain. Tail biopsies were collected at weaning, and offspring were screened for the genetic modifications by PCR (primer sequences in Supplemental Table 1 published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). Mice were fed Teklad Global Extruded Rodent Diet (soy protein free) ad libitum (Harlan Laboratories). For studies of tumorigenesis, animals were observed weekly for tumors and considered to be end stage when tumor diameter reached 1.5 cm (defined as tumor latency) or 9 months of age. Mice were housed and handled in accordance with the Guide for Care and Use of Laboratory Animals in AAALACaccredited facilities. All procedures were approved by the University of Wisconsin-Madison Animal Care and Use Committee.
Manipulation of estrogen activity
To observe the role of ER-mediated signals in pubertal elongation, females were treated with vehicle, or the ER␣ agonist, PPT (10 mg/kg), every fourth day starting at day 10 of age. One cohort also was treated with the ER antagonist, ICI (167 mg/ kg/wk sc), beginning at 3 weeks of age. Glands were examined at 12 weeks of age. To observe the role of ER-mediated signals in tumorigenesis, females were treated with the ER␣ agonist, PPT (10 mg/kg), every fourth day starting at day 10 of age until ductal elongation was complete (10 weeks of age), after which one cohort was treated with ICI until 9 months of age.
Analysis of ductal elongation
In order to examine the effect of locally elevated PRL on pubertal ductal elongation in the context of the homozygous ER␣(G525L) mutation, nontransgenic and NRL-PRL females with wild-type or mutant ER␣(G525L) were examined (F 2 generation, of the same mixed genetic background). Fourth inguinal mammary glands were fixed in 10% neutral buffered formalin overnight and stored in 70% ethanol. Whole mounts were stained with carmin, dehydrated with graded ethanol, and stored in glycerol until analysis. Ductal elongation was measured by dividing the area of ductal growth (length ϫ width) by the area of the mammary fat pad (length ϫ width).
Histologic examination of mammary tissue
Mammary glands were fixed in 10% neutral buffered formalin overnight, embedded in paraffin, and cut into 6-m sections. Morphologic analysis was performed on hematoxylin and eosin-stained slides. Ductal proliferation indices were determined by evaluating nuclear Ki67 staining in 1000 epithelial cells from at least 10 morphologically normal ducts. Tumors were classified as ER␣ϩ if more than 10% of the cells displayed nuclear ER␣ staining. Nuclear Stat5a/b labeling indices were determined by counting 100 tumor cells in 10 random microscopic fields by an investigator blind to the experimental group.
Real-time quantitative PCR
Total cellular RNA was isolated from whole mammary glands and tumors using RNeasy Kits (Qiagen, Inc.). For some experiments, poly(A)ϩ RNA was purified using the Ambion MicroPoly(A) Purist Kit (Life Technologies). cDNA was synthesized and quantitative real time-PCRs were carried out as described elsewhere (19) . Primers used are shown in Supplemental Table 1 .
Statistical analyses
Statistical analyses were performed using Prism v.5 (GraphPad Software, Inc.). Differences were considered significant at P Ͻ .05.
Results
PRL induces ER␣-dependent ductal elongation in the absence of ligand
At puberty, ovarian estrogens initiate the extension of the rudimentary mammary ductal tree throughout the mammary fat pad, a process that has been shown to be dependent on epithelial ER␣ (40, 41) . By 12 weeks of age, the ducts have elongated to fill nearly the entire fat pad, as observed in whole mounts of inguinal glands of nontransgenic and NRL-PRL females expressing wild-type ER␣ (89 Ϯ 11%, 91 Ϯ 11%, respectively). We used this physiologic event as one endpoint to determine whether PRL can activate ER␣ without estrogenic ligand. As shown in Figure 1 , mammary glands of nontransgenic females that were homozygous for the ER␣(G525L) mutation exhibited minimal ductal development, which was increased about 6-fold by administration of the synthetic ER␣-selective agonist, PPT, as previously reported (36) . Although elevated local PRL did not stimulate ductal elongation to the same extent as PPT, it did increase ductal development about 4-fold, which was reduced to baseline levels by ICI. Notably, PRL and PPT in combination strikingly promoted ductal elongation.
The ability of PRL to promote ER␣-dependent ductal elongation in the absence of estrogenic ligand was reflected in transcript levels for cytokeratins expressed by both basal (Krt5) and luminal (Krt18,19) epithelial cells (42) (Figure 2A ). Transcripts for other direct and indirect gene targets of estrogen at puberty (43, 44) were also elevated by locally increased PRL and reduced to levels not significantly different from ER␣(G525L) females by ICI, including mRNAs for the other components of the ER␣-regulatory network, Gata3 and FoxA1, the putative mediator of estrogen action in ductal elongation, amphiregulin, and other estrogen targets ( Figure 2B ). In contrast, mRNAs for ER␣, and IGF-1 and -2 were not altered by genotype or treatment, consistent with their expression in stroma as well as epithelia (Supplemental Figure 1) . Together, these data indicate that PRL can activate ER␣ in Figure 1 . PRL can stimulate estrogen-dependent ductal outgrowth and epithelial expansion in the absence of estrogenic ligand, and strongly cooperates with estrogen in this process Females of the genotypes shown were treated with vehicle, PPT, or ICI as described in Materials and Methods, and mammary glands were evaluated at 12 weeks of age. Ductal elongation was measured by dividing the area of the ductal growth by the area of the mammary fat pad. Data are represented as mean Ϯ SEM; n ϭ 5-6. Significant differences were determined by one-way ANOVA, followed by the Tukey posttest (*, P Ͻ .05; **, P Ͻ .005; ***, P Ͻ .0005). 
PRL/TGF␣ drives epithelial proliferation partially via ligand-independent activation of ER␣
The apparent insensitivity of mammary epithelial proliferation and tumorigenesis to estrogen ligand in NRL-PRL/TGF␣ females (26) suggested that ligand-independent activation of ER␣ may play an important role in the subsequent pathology. To minimize complexities from the mixed genetic background for these studies, we backcrossed the ER␣(G525L) mutation into the FVB/N strain. In order to expand the mammary epithelial subpopulation, females of all genotypes were treated with PPT until 10 weeks of age to mimic the effect of pubertal estrogen on ductal elongation. Thereafter, NRL-PRL/TGF␣ females with wild-type ER␣ or ER␣(G525L) were assigned to vehicle or ICI treatments. ICI markedly reduced uterine weight (Supplemental Figure 2) , demonstrating the efficacy of this treatment.
At 9 months of age or end stage, mammary glands were examined. Proliferation of morphologically normal luminal epithelium was assessed using Ki67. As previously reported (28), exposure to locally elevated PRL and TGF␣ dramatically increased proliferation of mammary ductal epithelia ( Figure 3B and Supplemental Figure 3) . Consistent with the observed independence from ovarian estrogen (26) , luminal epithelia in NRL-PRL/TGF␣/ ER␣(G525L) females proliferated at the same rate as that in NRL-PRL/TGF␣ females with wild-type ER␣. Treatment of both genotypes with ICI significantly decreased proliferation. However, despite this inhibition of ER-mediated signals, epithelial proliferation remained 3 times higher than in wild-type glands. These data indicate that a significant portion, but not all, of PRL/TGF␣-stimulated proliferation is mediated through ER.
In the absence of ER-mediated signals, PRL/TGF␣-promoted tumors develop more rapidly and exhibit a shift in histotype
In contrast to the inhibitory effect of ICI on proliferation of morphologically normal epithelium, ICI treatment accelerated tumorigenesis in NRL-PRL/TGF␣ females ( Figure 4A ). One hundred percent of NRL-PRL/TGF␣ females with wild-type ER␣ developed large mammary tumors with a latency similar to previous reports (26, 28) , which was significantly reduced by ICI treatment (P Ͻ .05). The ER␣(G525L) mutation increased the latency (P Ͻ .01) and decreased the incidence of mammary tumors (P Ͻ .05), compared with tumors from females with wildtype ER␣, perhaps reflecting the smaller epithelial popu- Figure 2 . Local PRL increases mammary transcripts by an ERdependent mechanism Females of the genotypes shown were treated with vehicle or ICI as described in Materials and Methods, and poly(A)ϩ RNA was isolated from mammary glands at 12 weeks of age. Specific transcripts were quantitated by qRT-PCR, normalizing to ␤-actin mRNA. Data are represented as mean Ϯ SEM; n ϭ 3-4. Significant differences were determined by one-way ANOVA, followed by the Tukey posttest. Different letters denote statistically significant differences among groups (a vs b, P Ͻ .05; a vs c, P Ͻ .01). A, Local PRL increases transcripts for cytokeratins expressed by both basal (Krt5) and luminal (Krt8, 18,19 ) epithelia. B, Local PRL increases transcripts for direct and indirect pubertal estrogen target genes. Relative proliferation was assessed by Ki67 staining as described in Materials and Methods. Significant differences were determined using the Kruskal-Wallis test, followed by the Mann-Whitney posttest (*, P Ͻ .05; ***, P Ͻ .001). Ki67 labeling of wild-type (WT) ducts was highly significantly lower than all genetically modified groups (P Ͻ .0001). Figure 4) and/or ovarian dysfunction in these animals (45) . However, ICI treatment increased the number of tumors in the NRL-PRL/TGF␣/ ER␣(G525L) females compared with that in control NRL-PRL/TGF␣/ER␣(G525L) females (P Ͻ .05). These data indicate that ICI exerts protumorigenic actions in this model.
lation (Supplemental
Tumors that developed in all genotypes, regardless of ICI treatment, were very heterogeneous and displayed many shared features (Table 1 and Figure 5 ). In contrast to the complex macrocystic tumors that developed in NRL-PRL/TGF␣ females on a standard diet (28), the tumors that developed on the soy-free diet in the current study were largely solid, with occasional restricted areas of complex microcysts in some tumors ( Figure 5C ). Limited studies indicated that the tumors were transplantable. Despite the shared elements, however, significant differences with genotype and ICI treatment were observed (Table 1) . Tumors from females with wild-type ER␣ without ICI treatment were predominantly glandular with microacinar structures, many of which contained copious secretions ( Figure 5A ). In contrast, tumors from these females treated with ICI or carrying the mutant ER␣(G525L) showed a significant shift to tumors that exhibited predominantly papillary histotypes ( Figure 5B ; P Ͻ .05, Fisher's exact test). Many of the tumors, especially the NRL-PRL/TGF␣ females without ICI treatment, contained large lipid droplets, consistent with the action of estrogen on metabolism (43) . Finally, a few of the tumors contained small squamous regions ( Figure 5D ). Of note, all tumors in all genotypes and treatments, including those that developed in the presence of postpubertal ICI, displayed high levels of ER␣ expression (Table 1 and Figure 5 , E and F), despite the inhibition of ER signals (Supplemental Figure  2) . In contrast, PRL/ TGF␣-induced tumors expressed little or no detectable progesterone receptor (PgR), similar to our previous study (26) .
To further investigate the role of estrogen signals in tumorigenesis induced by PRL/ TGF␣, we examined the effect of postpubertal ICI on select transcripts in NRL-PRL/TGF␣ tumors by quantitative real time-PCR. As expected, tumors that developed with chronic inhibition of ER signals displayed higher levels of ER␣ and lower levels of PgR mRNA, consistent with the ability of estrogen to inhibit ER␣ transcription (46) and stimulate PgR transcription (47) (Figure 6A ). mRNA for ER␤ was not detectable in these tumors, in contrast to abundant transcripts in the uterus and ovary (data not shown). Levels of Ki67 and survivin mRNAs did not reveal significant differences (data not shown). Although levels of mRNA for Krt5 and Krt 8, markers for basal and luminal cells, respectively, and the transcription factor, Gata3, were not altered by ICI (Figure 6B ), transcript levels of integrins associated with various epithelial subpopulations exhibited significant differences: ICI decreased transcripts for ␤1-integrin (P Ͻ .04) and increased those for ␣6-integrin (P Ͻ .03) (Figure 6C) . Moreover, tumors from animals treated with ICI had significantly higher levels of Stat5b transcripts ( Figure 6D ; P ϭ .007) and trended to have lower levels of Stat5a mRNA (P ϭ .06).
In light of the central role that Stat5a plays in the mediation of the physiological signals of PRL (48), and high expression of Stat5b in many breast cancers (48 -51), we further examined expression of these proteins in tumors induced by PRL/ TGF␣ in the presence and absence of ICI. As shown in Figure 7 , tumors that developed in the presence of ICI contained a greater number of cells containing nuclear Stat5b (P Ͻ .01) and fewer cells with nuclear Stat5 (P Ͻ .01) than tumors that developed in the absence of ICI. 
Discussion
ER␣ expression is the foremost prognostic and treatment indicator in breast cancer. Nonetheless, more than 25% of ER␣ϩ cancers fail to respond to antiestrogen treatments (1) . The interactions between PRL and estrogen in normal physiology and the strong association of PRL with the risk, progression, and therapeutic responsiveness of ER␣ϩ breast cancer stress the importance of understanding the role of PRL in this cancer subtype. Ligand-independent activation of ER␣ has been suggested as one mechanism whereby tumors escape endocrine treatments (2-4). However, although evidence from our laboratory and others implicates PRL action by this mechanism in breast cancer cells in vitro (25) (26) (27) , the potency of this mechanism in vivo has not been demonstrated. The studies described herein demonstrate that PRL can activate ER␣ 9/9 ER␣(G525L) ϩ ICI Tumors were highly heterogeneous, containing multiple different regions of distinct histotypes. More than 10% of tumor cells with nuclear ER␣ staining were considered to be ER␣ϩ. Different letters denote statistical differences among groups (P Ͻ 0.05; Fisher's exact test). in the absence of estrogenic ligand in vivo, driving ER␣-dependent ductal elongation and gene expression at puberty. Moreover, they show that the cooperative stimulation of epithelial proliferation by PRL and the EGFR ligand, TGF␣, is partially mediated by ER, independent of estrogen ligand. However, inhibition of postpubertal ER signals accelerates tumorigenesis and shifts the histotype of the resulting tumors, despite high levels of ER␣ expression.
The ability of locally elevated PRL to drive ER␣-dependent ductal elongation (40, 41) in NRL-PRL/ ER␣(G525L) females demonstrates the efficacy of PRLinduced ligand-independent activation of ER␣ in vivo. The cooperation between PRL and the estrogen agonist, PPT, in ductal development likely reflects the multiple levels of cross talk between these hormones in mammary epithelial cells, including increasing expression of the other's receptors (52) (53) (54) and cross talk to tethered ER␣-mediated signals, such as AP-1 (55, 56) , in addition to PRLinduced activation of the AF-1 domain of ER␣ (25) (26) (27) . Our findings are consistent with the ability of supplemental 17␤-estradiol to cooperate with transgenic PRL in mammary tumorigenesis (20) . The increased efficacy of an aromatase inhibitor and PRLR-neutralizing antibody to reduce growth of 7,12-dimethylbenz(␣)anthracene-induced ER␣ϩ rat mammary tumors (57) indicates that the potency of this interaction may be exploited to enhance therapeutic strategies.
Cross talk between PRL and the EGFR ligand, TGF␣, abrogates mitogenic responsiveness of morphologically normal mammary epithelial cells to 17␤-estradiol (26) , confirmed here by the failure of the ER␣(G525L) mutant to alter ductal proliferation in these animals. Notably, it is the combination of the PRL and TGF␣ transgenes that confers this resistance; proliferation of ductal epithelium in single transgenic NRL-PRL and NRL-TGF␣ females is highly estrogen responsive (26) . Despite this insensitivity to ligand, our findings here demonstrate that ER-dependent signals mediate about one third of PRL/TGF␣-induced proliferation. Our results are consistent with the strong cross talk of these hormones/cytokines to signaling cascades that lead to phosphorylation of ER␣ at residues in the AF-1 domain associated with activation in the absence of ligand (21-24, 26, 28 -31) . Development of antibodies that recognize modifications of murine ER will assist in understanding the scope of posttranslational modifications initiated by PRL and TGF␣ individually and in combination, which result in insensitivity to ligand as well as ligand-independent activation. Strikingly, however, even in the absence of ER-mediated signals, PRL/ TGF␣ cross talk still elevates proliferation more than 3-fold above that observed in wild-type ducts, underscoring the strength of their interaction in disease processes.
PRL/TGF␣-driven tumorigenesis in this model resulted in strongly ER␣ϩ tumors, regardless of ICI treatment, indicating that postpubertal ER-mediated signals are not necessary for luminal tumorigenesis. These findings support a minimal contribution of estrogen to ER␣ϩ breast cancer, as suggested by the epidemiologic data indicating increased ER␣ϩ tumors after menopause (58, 59) . However, in contrast to the positive contribution of ER-mediated signals to the proliferation of morphologically normal ductal epithelium in NRL-PRL/TGF␣ females, postpubertal inhibition of ER signals accelerated tumorigenesis. Moreover, tumors that developed with chronic inhibition of ER-mediated signals had higher levels of transcripts for ␣6-integrin and lower levels of ␤1-integrin, a combination found in adult mammary stem cells (60) and a stem cell-like subpopulation of MCF-7 cells (61) . These findings mimic the clinical link between weak ex- endo.endojournals.orgpression of estrogen-driven genes and poor outcomes, features of the luminal B breast cancer subtype that frequently are attributed to heightened growth factor activity (62, 63) . Interestingly, stable expression of ER␣(S118A) or ER␣(S167A) in MCF7 cells, both likely targets of the robust cross talk of TGF␣ and PRL to ERK1/2 and AKT in these cells (25, 26, 28) , increases growth and invasiveness (64) . Together with the literature, our data support a model of ER-driven differentiated behaviors, despite the mitogenic effects of these signals. Interestingly, ER-mediated signals modulated the balance of Stat5a/ Stat5b expression. Stat5a is the major Stat5 isoform expressed physiologically in the mammary gland, but Stat5b is also highly expressed in many breast cancers (48 -51) . Although control of the relative levels of the Stat5 isoforms is not well understood, acute estrogen treatment of mice increases mammary Stat5a mRNA (65) , consistent with our data. PRL can activate both Stat5 isoforms, but Stat5a is the best-characterized mediator of PRL actions during pregnancy (48, 49, 66) . Growth factors can activate Stat5b via kinases that are also nodes of signaling cross talk with PRL (67, 68) . In part because of a shared amino acid sequence surrounding Tyr 694/699, a phosphorylated residue necessary for dimerization and nuclear translocation (69), many studies have not distinguished these isoforms. However, it was reported recently that reduced nuclear Stat5a, but not Stat5b, is associated with higher risk of resistance to antiestrogen therapies and worse outcomes (49) . Multiple studies have demonstrated the complex relationship between estrogen and Stat5 signals, with disparate findings, depending on experimental design and readout (67) . Interestingly, activated ER␣ suppresses EGF signals to Stat5b in breast cancer cells in vitro (70) , suggesting that ICI may strengthen Stat5b-mediated signals in our model. Furthermore, the Src-EGFR-Stat5b cascade can induce tamoxifen resistance (71) . In support of the clinical findings demonstrating distinct roles for the Stat5 isoforms, accumulating studies demonstrate functional differences (72, 73) and a large subset of differentially regulated genes (49) . Notably, Stat5b, but not Stat5a, mediates PRL-induced ␣6-integrin mRNA in MCF-7 cells (49), consistent with our findings. Together, our studies provide insight into the network of interactions among PRL, growth factors, and estrogen in the complex in vivo environment and provide a robust model for further investigation.
In summary, our data extend our understanding of the synergistic cross talk between PRL and estrogen, revealing ligand-independent activation of ER␣ as an additional underlying mechanism, which may impact both normal mammary function as well as pathology. Our findings underscore the ability of PRL to promote luminal breast cancer and its strong cooperation with growth factors in oncogenesis and point to the contributions of PRL to the intricate cross talk between growth factors and estrogen signals, including altered responsiveness to estrogen ligand. These studies support the potential for therapeutics that target PRL alone or in combination with estrogen-or growth factor-directed therapies. However, the altered phenotype and accelerated development of the tumors that develop in the presence of the antiestrogen underscore the importance of validated biomarkers for treatment selection.
